CN117597341A - 磺酰胺衍生物、其制备方法及其在医药上的应用 - Google Patents

磺酰胺衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN117597341A
CN117597341A CN202280046780.6A CN202280046780A CN117597341A CN 117597341 A CN117597341 A CN 117597341A CN 202280046780 A CN202280046780 A CN 202280046780A CN 117597341 A CN117597341 A CN 117597341A
Authority
CN
China
Prior art keywords
cancer
compound
group
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280046780.6A
Other languages
English (en)
Chinese (zh)
Inventor
张晓敏
胡伟民
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN117597341A publication Critical patent/CN117597341A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280046780.6A 2021-08-10 2022-08-10 磺酰胺衍生物、其制备方法及其在医药上的应用 Pending CN117597341A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110913249 2021-08-10
CN2021109132491 2021-08-10
CN202111142090 2021-09-28
CN2021111420904 2021-09-28
CN202111500231 2021-12-09
CN2021115002315 2021-12-09
PCT/CN2022/111395 WO2023016484A1 (zh) 2021-08-10 2022-08-10 磺酰胺衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CN117597341A true CN117597341A (zh) 2024-02-23

Family

ID=85200573

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280046780.6A Pending CN117597341A (zh) 2021-08-10 2022-08-10 磺酰胺衍生物、其制备方法及其在医药上的应用

Country Status (10)

Country Link
US (1) US20250145637A1 (https=)
EP (1) EP4385989A4 (https=)
JP (1) JP2024529068A (https=)
KR (1) KR20240046530A (https=)
CN (1) CN117597341A (https=)
AU (1) AU2022325367A1 (https=)
CA (1) CA3228411A1 (https=)
MX (1) MX2024001777A (https=)
TW (1) TW202321263A (https=)
WO (1) WO2023016484A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118556053A (zh) 2021-11-16 2024-08-27 英矽智能科技知识产权有限公司 赖氨酸乙酰基转移酶6a(kat6a)抑制剂及其用途
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
KR20250006833A (ko) 2022-03-28 2025-01-13 아이소스테릭스, 인코포레이티드 라이신 아세틸 전이효소의 myst 계열의 억제제
KR20250143814A (ko) * 2023-02-10 2025-10-02 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 설폰아미드 유도체 결정 형태 및 이의 제조 방법
WO2024189598A2 (en) 2023-03-16 2024-09-19 Olema Pharmaceuticals, Inc. Acylsulfonamide kat6a inhibitors
CN120981721A (zh) * 2023-03-30 2025-11-18 辉瑞大药厂 Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法
AU2024290895A1 (en) 2023-07-04 2026-01-29 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Kat6 inhibitor
WO2025098417A1 (zh) * 2023-11-08 2025-05-15 再和医药科技（苏州）有限公司 磺酰胺类化合物及其应用
WO2025101942A1 (en) * 2023-11-10 2025-05-15 Prelude Therapeutics Incorporated Kat6 targeting compounds
AR134697A1 (es) * 2023-12-18 2026-03-04 Ideaya Biosciences Inc Compuestos químicos y sus usos

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150183802A1 (en) * 2013-12-30 2015-07-02 Novartis Ag Tricyclic sulfonamide derivatives
CN105492430A (zh) * 2013-03-15 2016-04-13 基因泰克公司 取代的苯并噁唑及其使用方法
CN112334466A (zh) * 2018-06-20 2021-02-05 Ctxt私人有限公司 化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
HU225047B1 (en) * 1991-03-28 2006-05-29 Eisai Co Ltd Heterocyclic-piperidin-derivatives, pharmaceutical compositions containing them and process for their production
WO2002074746A1 (en) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
KR100965021B1 (ko) * 2002-02-22 2010-06-21 바이엘 파마슈티칼스 코포레이션 과다증식성 질환 치료에 유용한 벤조푸란 및 벤조티오펜유도체
AU2006281803B9 (en) * 2005-08-18 2013-05-30 Genmab A/S Therapy with CD4 binding peptides and radiation
JP6568926B2 (ja) * 2014-03-20 2019-08-28 カペラ セラピューティクス，インコーポレーテッド 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017218960A1 (en) 2016-06-17 2017-12-21 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
MX2020007131A (es) 2017-11-29 2021-01-08 Epizyme Inc Inhibidores de histona acetiltransferasa de la familia myst.
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
KR20210057767A (ko) * 2018-09-07 2021-05-21 치아타이 티안큉 파마수티컬 그룹 주식회사 Crbn단백질에 작용하는 삼환식 화합물
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
CA3137472A1 (en) 2019-04-25 2020-10-29 Bayer Aktiengesellschaft Acyl sulfonamides for treating cancer
DK4299135T3 (da) * 2019-06-18 2025-09-08 Pfizer Benzisoxazol-sulfonamid-derivater
US12545669B2 (en) 2019-06-19 2026-02-10 Pfizer Inc. Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492430A (zh) * 2013-03-15 2016-04-13 基因泰克公司 取代的苯并噁唑及其使用方法
US20150183802A1 (en) * 2013-12-30 2015-07-02 Novartis Ag Tricyclic sulfonamide derivatives
CN112334466A (zh) * 2018-06-20 2021-02-05 Ctxt私人有限公司 化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂

Also Published As

Publication number Publication date
MX2024001777A (es) 2024-02-29
JP2024529068A (ja) 2024-08-01
AU2022325367A1 (en) 2024-02-08
WO2023016484A1 (zh) 2023-02-16
CA3228411A1 (en) 2023-02-16
EP4385989A4 (en) 2024-12-18
KR20240046530A (ko) 2024-04-09
EP4385989A1 (en) 2024-06-19
US20250145637A1 (en) 2025-05-08
TW202321263A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
CN117597341A (zh) 磺酰胺衍生物、其制备方法及其在医药上的应用
TW202322819A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
TW202325298A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
WO2020125513A1 (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CN120858101A (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
CN107033097B (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
CN114149423B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN115594695A (zh) 大环类化合物、其制备方法及其在医药上的应用
TW202102505A (zh) 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用
TW201934554A (zh) 吡唑并[1,5-a][1,3,5]三<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 d10999.TIF" img-content="tif" orientation="portrait" inline="yes"></img>-2-胺類衍生物、其製備方法及其在醫藥上的應用
NL2000336C2 (nl) Spirocyclische derivaten.
CN118184658A (zh) Usp1抑制剂
CN119365468A (zh) 稠合二环类化合物、其制备方法及其在医药上的应用
TWI828289B (zh) 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法
EP3683206A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
CN112996783A (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
JP2022502484A (ja) キナーゼ阻害活性を有する芳香族複素環式化合物
WO2022166810A1 (zh) 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
AU2024319888A1 (en) Heteroaryl compound, preparation method therefor, and use thereof in medicine
CN115611877A (zh) 磺酰胺类化合物、其制备方法及其在医药上的应用
CN109206435B (zh) 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
CN107056754B (zh) 内嵌脲类结构的wnt通路抑制剂
WO2025036382A1 (zh) 一种磺酰胺类化合物、其制备方法及用途
CN119161325A (zh) 内酰胺类化合物、其制备方法及其在医药上的应用
KR20260029377A (ko) 암 및 염증성 질환 치료에 사용하기 위한 이미다조[1,2-α]피리딘 화합물 및 그 화합물의 제조 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40108010

Country of ref document: HK